Trial Radar AI | ||
|---|---|---|
Clinical Trial NCT07476586 for Healthy Volunteers is not yet recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here. | ||
One study matched filter criteria
Card View
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics of GenSci161 in Healthy Adult Participants Phase 1 44 Biomarker-Driven Randomized Double-Blind Placebo-Controlled
Clinical Trial NCT07476586 is designed to study Other for Healthy Volunteers. This Phase 1 interventional study is not yet recruiting. Enrollment is planned to begin on 23 April 2026 until the study accrues 44 participants. Led by Changchun GeneScience Pharmaceutical Co., Ltd., this study is expected to complete by 10 August 2027. The latest data from ClinicalTrials.gov was last updated on 17 March 2026.
Brief Summary
To Evaluate the Safety and Tolerability, Pharmacokinetics and Biomarker of GenSci161 in a Randomized, Double-blind, Placebo-controlled Study in Healthy Adult Participants.
Official Title
A Single-center, Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Biomarker Characteristics of a Single Subcutaneous Injection of GenSci161 Injection in Healthy Adult Participants
Conditions
Healthy VolunteersOther Study IDs
- GenSci161-101
NCT ID Number
Start Date (Actual)
2026-04-23
Last Update Posted
2026-03-17
Completion Date (Estimated)
2027-08-10
Enrollment (Estimated)
44
Study Type
Interventional
PHASE
Phase 1
Status
Not yet recruiting
Primary Purpose
Other
Design Allocation
Randomized
Interventional Model
Parallel
Masking
Quadruple
Arms / Interventions
| Participant Group/Arm | Intervention/Treatment |
|---|---|
ExperimentalGenSci0161 Single ascending doses of GenSci161 administered subcutaneous injection | GenSci161 Administered subcutaneous injection |
Placebo ComparatorPlacebo All subjects will receive matching placebo | Placebo Administered subcutaneous injection |
Primary Outcome Measures
Secondary Outcome Measures
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Incidence and severity of treatment-emergent adverse events (TEAEs)/serious adverse events (SAEs) and other safety measures | Day1- Day183 |
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Area under the concentration-time curve from zero up to a definite time t (AUC0-t) | Day1- Day183 | |
Area under the concentration-time curve from zero up to infinity (AUC0-∞) | Day1- Day183 | |
Maximum concentration (Cmax) | Day1- Day183 | |
Terminal elimination half-life (t1/2) | Day1- Day183 | |
Apparent clearance (CL/F) | Day1- Day183 | |
Apparent volume of distribution (Vd/F) | Day1- Day183 | |
Anti-drug antibody (ADA) and neutralizing antibody(Nab) | Day1- Day183 | |
Upper limit of the two-sided 90% confidence interval for ∆∆QTcF corresponding to the maximum geometric mean of Cmax obtained from the study | Day1- Day15 |
Participation Assistant
Eligibility Criteria
Eligible Ages
Adult
Minimum Age
18 Years
Eligible Sexes
All
Accepts Healthy Volunteers
Yes
- Healthy adult male or female participants, aged 18 to 45 years (inclusive) at the time of signing the informed consent form (ICF).
- Male body weight ≥ 50 kg and female body weight ≥ 45 kg at screening; body mass index (BMI) between 18 and 28 kg/m² (inclusive).
- In good general condition as determined by medical history, screening period assessments, such as physical examination, vital signs, ECG, laboratory tests, and imaging examinations, with all results within reference ranges or deemed clinically insignificant by the investigator.
- Male and female participants of childbearing potential must agree to use highly effective contraception from screening until 6 months after the last dose. From the time of signing the ICF until 6 months after the last dose, they must have no plans for conception, sperm donation, egg donation, or egg cryopreservation. Female participants must have had no unprotected sexual intercourse within 14 days prior to the first dose.
- Participants must voluntarily sign the ICF, be able to understand and comply with the requirements of this trial protocol, and complete scheduled follow-up visits in a timely manner.
- History of hypersensitivity to GenSci161, any of its excipients, or similar compounds; or a history of allergic diathesis; or a history of allergic diseases.
- Severe trauma or major surgical procedure (e.g., coronary artery bypass grafting, organ resection, gynecological surgery) within 12 months prior to screening, or planning to undergo any surgery (including cosmetic procedures) during the trial period.
- Presence of significant active systemic or local infection (including, but not limited to, bacterial, viral, fungal, or parasitic \[helminth\] infections) at any time from 4 weeks prior to screening until the day of randomization.
- Intolerance to abdominal subcutaneous injection, or the presence of tattoos, sunburn, scars, or any other factors at the intended injection site that may interfere with site assessment.
- History or current presence of any clinically significant, poorly controlled chronic disease or organ dysfunction that, in the investigator's judgment, could compromise the trial's conduct. This includes, but is not limited to, disorders of the following systems: neuropsychiatric, cardiovascular, urological, gastrointestinal, respiratory, musculoskeletal, metabolic, endocrine, hematologic, immunologic, and dermatologic, as well as any other major medical conditions and malignancies (with the exception of adequately treated or resected, and resolved non-metastatic basal cell carcinoma or squamous cell carcinoma of the skin).
- A positive result at screening for hepatitis C virus antibody (HCV-Ab), human immunodeficiency virus antibody (HIV-Ab), treponema pallidum particle agglutination assay (TPPA), or hepatitis B virus (HBV) infection (defined as a positive hepatitis B surface antigen \[HBsAg\] and/or a positive hepatitis B core antibody \[HBcAb\] result).
- Administration of any live or live-attenuated vaccine within 12 weeks prior to screening or planning to receive any live or live-attenuated vaccine (with the exception of inactivated influenza vaccine) during the trial period.
- Any other condition that, in the judgment of the investigator, would make the participant unsuitable for participation in this clinical trial.
Changchun GeneScience Pharmaceutical Co., Ltd.Study Central Contact
Contact: ShuQin Jiang, +86 18036617122, [email protected]
1 Study Locations in 1 Countries
Shanghai Municipality
Huashan Hospital Affiliated to Fudan University, Shanghai, Shanghai Municipality, 200000, China
Jing Zhang, Doctor, Contact, 021-52887926, [email protected]
Guoying Cao, Master, Contact, 021-52888195, [email protected]